Sign in
4

Changes in Ownership

CytomX Therapeutics, Inc. Filed Acc 0001140361-15-046030

Chief Scientific Officer and acquired 8,917 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Kavanaugh William Michael · Chief Scientific Officer and

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2015-12-31 Exercise or conversion : show line 1 in the form +8,917 $6.61 $58,983 13,917 D

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2015-12-31 Exercise or conversion : show line 2 in the form Employee Stock Option (right to buy) −8,917 76,688 D
Loading xslF345X03/doc1.xml…